ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

被引：0

作者：

Kiladjian, Jean-Jacques ^{[1
]}

Marin, Francisca Ferrer ^{[2
]}

Al-Ali, Haifa Kathrin ^{[3
]}

Alvarez-Larran, Alberto ^{[4
]}

Beggiato, Eloise ^{[5
]}

Bieniaszewska, Maria ^{[6
]}

Breccia, Massimo ^{[7
]}

Buxhofer-Ausch, Veronika ^{[8
]}

Cerna, Olga ^{[9
,10
]}

Crisan, Ana Manuela ^{[11
]}

Danaila, Catalin ^{[12
]}

De Stefano, Valerio ^{[13
]}

Dohner, Konstanze ^{[14
]}

Empson, Victoria ^{[15
]}

Tybor, Joanna Gora ^{[16
]}

Griesshammer, Martin ^{[17
]}

Grosicki, Sebastian ^{[18
]}

Guglielmelli, Paola ^{[19
]}

Gutierrez Sr, Valentin Garcia ^{[20
]}

Heidel, Florian ^{[21
]}

Illes, Arpad ^{[22
]}

James, Chloe ^{[23
]}

Koschmieder, Steffen ^{[24
]}

Maria-Theresa, Krauth ^{[25
]}

Krejcy, Kurt ^{[15
]}

Lazaroiu, Mihaela Cornelia ^{[26
]}

Mayer, Jiri ^{[27
]}

Nagy, Zsolt ^{[28
]}

Palandri, Francesca ^{[29
]}

Pappa, Vasiliki ^{[30
]}

Reiter, Andreas ^{[31
]}

Sacha, Tomasz ^{[32
]}

Schlager, Stefanie ^{[15
]}

Schmidt, Stefan Ulrich ^{[33
]}

Terpos, Evangelos ^{[34
]}

Tomuleasa, Ciprian ^{[35
]}

Torregrosa, Jose Miguel ^{[36
]}

Unger, Martin ^{[15
]}

Woelfler, Albert ^{[37
]}

Xicoy, Blanca ^{[38
]}

Klade, Christoph ^{[15
]}

机构：

[1] Hop St Louis, Ctr Invest Clin, Paris, France

[2] HU Morales Meseguer, Serv Anat Patol, Murcia, Spain

[3] Univ Med Halle, Krukenberg Canc Ctr Halle, Halle, Germany

[4] Hosp Clin Barcelona, ICMHO, Hematol Dept, Barcelona, Spain

[5] AOU Citta Salute & Sci, SC Clin Pharmacol, Turin, Italy

[6] INFN Torino, Turin, Italy

[7] Univ Clin Ctr, Gdansk, Poland

[8] Sapienza Univ Rome, Rome, Italy

[9] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Fac Med 3, Dept Hematol, Prague, Czech Republic

[10] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Hematol, Prague, Czech Republic

[11] Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania

[12] Reg Inst Oncol, Dept Clin Hematol, Iasi, Romania

[13] Catholic Univ, Dept Urol, Fdn Policlin Univ A Gemelli IRCCS, Med Sch, Rome, Italy

[14] Univ Hosp Ulm, Dept Radiol, Ulm, Germany

[15] AOP Hlth, Vienna, Austria

[16] Med Univ Lodz, Copernicus Mem Hosp Lodz, Dept Biostat & Translat Med, Dept Hematooncol, Lodz, Poland

[17] Univ Bochum, Univ Clin Hematol Oncol Hemostaseol & Palliat Care, Johannes Wesling Med Ctr Minden, Bochum, Germany

[18] Med Univ Silesia, Fac Hlth Sci Bytom, Dept Hematol & Canc Prevent, Katowice, Poland

[19] Univ Studi Firenze, Florence, Italy

[20] Univ Alcala, Hosp Univ Ramon & Cajal, Dept Urol, Inst Ramon & Cajal Invest Sanitaria IRYCIS, Madrid, Spain

[21] Hannover Med Sch, Dept Hematol, Hemostasis Oncol & Stem Cell Transplantat, Hannover, Germany

[22] Univ Debrecen, Clin Ctr, Debrecen, Hungary

[23] Univ Bordeaux, Biol Cardiovasc Dis, Inserm, UMR1034, Pessac, France

[24] Aachen Bonn Cologne Dusseldorf CIO ABCD, Ctr Integrated Oncol, Aachen, Germany

[25] Med Univ Vienna, Clin Div Hematol & Hemostaseol, Dept Internal Medicine1, Vienna, Austria

[26] Policlin Diagnost Rapid, Brasov, Romania

[27] Masaryk Univ, Univ Hosp Brno, Brno, Czech Republic

[28] Semmelwe Egyet, Sportorvostan Tanszek, Budapest, Hungary

[29] Ist Ematol Seragnoli, IRCCS Azienda Ospedaliero Universitaria Bologna, Bologna, Italy

[30] Univ Gen Hosp Attikon, Dept Internal Med & Res Unit 2, Athens, Greece

[31] Univ Med Ctr Mannheim, Dept Hematol & Oncol, Mannheim, Germany

[32] Jagiellonian Univ Hosp Krakow, Krakow, Poland

[33] Med Univ Innsbruck, Dept Internal Med Hematol & Oncol 5, Innsbruck, Austria

[34] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Drosia, Greece

[35] Iuliu Hatieganu Univ Med & Pharm, MedFuture Res Ctr Advance Med, Cluj Napoca, Romania

[36] Univ Poitiers, Chu Poitiers, Poitiers, France

[37] Med Univ Graz, Oncol, Graz, Austria

[38] Univ Autonoma Barcelona, Inst Catala Oncol Badalona, Josep Carreras Leukemia Res Inst, Hosp Univ Germans Trias & Pujol, Barcelona, Spain

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199028

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6635 / 6637

页数：3

共 50 条

[31] EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.
Masarova, Lucia
Mascarenhas, John
Qin, Albert
Shih, Weichung
Sato, Toshiaki
Urbanski, Raymond
Zagrijtschuk, Oleh
Zimmerman, Craig
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[32] A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis
Abu-Zeinah, Ghaith
Qin, Albert
Gill, Harinder
Komatsu, Norio
Mascarenhas, John
Shih, Weichung Joe
Zagrijtschuk, Oleh
Sato, Toshiaki
Shimoda, Kazuya
Silver, Richard T.
Mesa, Ruben
ANNALS OF HEMATOLOGY, 2024, 103 (09) : 3573 - 3583
[33] A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia
Masarova, Lucia
Mascarenhas, John
Shih, Weichung
Tashi, Tsewang
Sato, Toshiaki
Urbanski, Raymond
Zagrijtschuk, Oleh
Zimmerman, Craig
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S405 - S406
[34] Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
Barbui, Tiziano
Vannucchi, Alessandro Maria
De Stefano, Valerio
Masciulli, Arianna
Carobbio, Alessandra
Ferrari, Alberto
Ghirardi, Arianna
Rossi, Elena
Ciceri, Fabio
Bonifacio, Massimiliano
Iurlo, Alessandra
Palandri, Francesca
Benevolo, Giulia
Pane, Fabrizio
Ricco, Alessandra
Carli, Giuseppe
Caramella, Marianna
Rapezzi, Davide
Musolino, Caterina
Siragusa, Sergio
Rumi, Elisa
Patriarca, Andrea
Cascavilla, Nicola
Mora, Barbara
Cacciola, Emma
Mannarelli, Carmela
Loscocco, Giuseppe Gaetano
Guglielmelli, Paola
Betti, Silvia
Lunghi, Francesca
Scaffidi, Luigi
Bucelli, Cristina
Vianelli, Nicola
Bellini, Marta
Finazzi, Maria Chiara
Tognoni, Gianni
Rambaldi, Alessandro
LANCET HAEMATOLOGY, 2021, 8 (03): : E175 - E184
[35] A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia
Verstovsek, Srdan
Mesa, Ruben
Mascarenhas, John
Tashi, Tsewang
Shih, Weichung
Sato, Toshiaki
Urbanski, Raymond
Zagrijtschuk, Oleh
Zimmerman, Craig
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S342 - S343
[36] Phase III trial of PEG intron vs interferon alfa-2b for the initial treatment of chronic myelogenous leukemia (CML).
Michallet, M
Delain, M
Maloisel, F
Hellmann, A
Rosas, A
Silver, R
Tendler, C
BLOOD, 2001, 98 (11) : 348A - 348A
[37] Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/Pegasys®
Gilreath, Jeffrey A.
Tashi, Tsewang
Kim, Soo Jin
Hickman, Kimberly
Prchal, Josef T.
BLOOD, 2018, 132
[38] Treatment with ropeginterferon alfa-2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea: one-year results from a phase 2 study
Yoon, Seug Yun
Lee, Sung-Eun
BLOOD RESEARCH, 2024, 59 (01)
[39] Safety and efficacy of interferon alfa-2b and ribavirin combination therapy for the treatment of hepatitis C in patients coinfected with HIV.
Bini, EJ
Reid, M
Mannix, RA
Wu, B
HEPATOLOGY, 2001, 34 (04) : 335A - 335A
[40] Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial
Qin, Albert
Ho, Ming-Chih
Tsai, Chan-Yen
Liu, Chun-Jen
Chen, Pei-Jer
HEPATOLOGY INTERNATIONAL, 2025,

← 1 2 3 4 5 →